UroAlert - GU Oncology Daily

December 10, 2024

Videos

Peer-to-Peer Clinical Conversations

Response and Progression Criteria for PSMA PET: Imaging Prostate Cancer Outcomes - Wolfgang Fendler

Wolfgang Fendler

Oliver Sartor and Wolfgang Fendler explore the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer.

Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer - Sarah Psutka

Sarah Psutka

Sarah Psutka examines the expanded access program (EAP) for cretostimogene in BCG-unresponsive bladder cancer.

Beyond the Abstracts

A US Real-World Study of Treatment Patterns and Outcomes in Localized or Locally Advanced Prostate Cancer Patients - Beyond the Abstract

Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis) - Beyond the Abstract

Conference Coverage

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation

SUO 2024: Sustainability in Prostate Cancer Care

SUO 2024: Biology of Cancer Metastases

SUO 2024: Game Changing Team Science

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Safety and efficacy of the MP1000 surgical system in robot-assisted radical cystectomy: A prospective study.

Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.

Metastasis Development in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract

Renal Cancer

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.

Diagnostic and prognostic potential of FBXO8 expression in kidney renal clear cell carcinoma and its regulation of renal adenocarcinoma cells.

Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.

Prostate Cancer

Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery.

Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer.

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy.

Survival Outcomes and Recurrence Patterns Following Focal High-intensity Focused Ultrasound Treatment for Localized Prostate Cancer: Insights on Patient Selection and Lessons Learned.

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.

Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience.

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.

Docetaxel Versus Androgen-Receptor Signaling Inhibitors as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC